# Exelixis clinical trials: 57 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 57 trials with Exelixis as lead sponsor, 10 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Exelixis: 57 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/exelixis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 57
- Recruiting or not yet: 10
- Read on: November 19, 2026

## Trials

The 25 newest of 57, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 29, 2026 | NCT07845786 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | Exelixis | Phase 2 | Recruiting | Squamous Non-Small Cell Lung Cancer (NSCLC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845786) |
| August 19, 2026 | NCT07773454 | Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors | Exelixis | Phase 1 | Not yet recruiting | Cancer, Pediatric Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773454) |
| August 6, 2026 | NCT07750158 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular... | Exelixis | Phase 3 | Recruiting | Colorectal Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750158) |
| June 2, 2026 | NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | Exelixis | Phase 3 | Enrolling by invitation | Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)... | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620574) |
| February 24, 2026 | NCT07428616 | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma | Exelixis | Phase 2 | Recruiting | Meningioma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07428616) |
| August 14, 2025 | NCT07123103 | A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Exelixis | Phase 1 | Recruiting | Solid Tumors | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123103) |
| May 8, 2025 | NCT06962332 | Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) | Exelixis | Phase 1 | Recruiting | Hepatic Impairment, Moderate Hepatic Impairment | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06962332) |
| April 30, 2025 | NCT06952010 | A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors | Exelixis | Phase 1 | Recruiting | Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor | 303 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952010) |
| April 24, 2025 | NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Exelixis | Phase 2/3 | Recruiting | Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943755) |
| October 8, 2024 | NCT06630247 | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors | Exelixis | Phase 1 | Terminated | Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis... | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06630247) |
| August 9, 2024 | NCT06545331 | Study of XB010 in Subjects With Solid Tumors | Exelixis | Phase 1 | Recruiting | Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC... | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06545331) |
| January 5, 2024 | NCT06191796 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma... | Exelixis | Phase 1 | Terminated | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06191796) |
| October 13, 2023 | NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck... | Exelixis | Phase 2/3 | Active not recruiting | Head and Neck Squamous Cell Carcinoma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06082167) |
| July 6, 2023 | NCT05932862 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Exelixis | Phase 1 | Active not recruiting | Advanced Solid Tumor | 429 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05932862) |
| January 10, 2023 | NCT05678673 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | Exelixis | Phase 3 | Active not recruiting | Non-Clear Cell Renal Cell Carcinoma | 317 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05678673) |
| June 21, 2022 | NCT05425940 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer | Exelixis | Phase 3 | Active not recruiting | Colorectal Cancer | 901 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05425940) |
| January 4, 2022 | NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | Exelixis | Phase 1 | Recruiting | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid... | 1,394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05176483) |
| December 3, 2021 | NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Exelixis | Phase 1 | Terminated | Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma... | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05144347) |
| June 14, 2021 | NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Exelixis | Phase 1 | Completed | Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant... | 269 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04925284) |
| January 27, 2021 | NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Exelixis | Phase 1 | Terminated | Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04726332) |
| June 24, 2020 | NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | Exelixis | Phase 3 | Active not recruiting | Metastatic Prostate Cancer, Prostate Adenocarcinoma | 575 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04446117) |
| May 3, 2019 | NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell... | Exelixis | Phase 3 | Active not recruiting | Renal Cell Carcinoma | 855 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03937219) |
| February 19, 2019 | NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | Exelixis | Phase 1 | Active not recruiting | Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant... | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03845166) |
| November 28, 2018 | NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who... | Exelixis | Phase 3 | Active not recruiting | Hepatocellular Carcinoma | 837 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03755791) |
| October 1, 2018 | NCT03690388 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed... | Exelixis | Phase 3 | Active not recruiting | Differentiated Thyroid Cancer | 187 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03690388) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 32 |
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Phase 2/3 | 2 |
| Phase 3 | 13 |
| Phase 4 | 1 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 18 |
| Terminated | 14 |
| Active not recruiting | 11 |
| Recruiting | 9 |
| Enrolling by invitation | 1 |
| Approved for marketing | 1 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 18 |
| Carcinoma, Renal Cell | 8 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Prostatic Neoplasms | 7 |
| Colorectal Neoplasms | 7 |
| Carcinoma, Hepatocellular | 6 |
| Neoplasm Metastasis | 4 |
| Triple Negative Breast Neoplasms | 4 |
| Carcinoma, Medullary | 4 |
| Thyroid Neoplasms | 4 |
| Lymphoma | 3 |
| Ovarian Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Breast Neoplasms | 3 |
| Carcinoma, Transitional Cell | 3 |
| Thyroid Cancer, Papillary | 3 |
| Glioblastoma | 3 |
| Brain Neoplasms | 3 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
| Pain | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Neuroendocrine Tumors | 2 |
| Esophageal Squamous Cell Carcinoma | 2 |
| Melanoma | 2 |
| Glioma | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Road contractors in the United States](https://specstream.ai/data/businesses/road-contractors/united-states)
- [Fitness equipment wholesalers in the United States](https://specstream.ai/data/businesses/fitness-equipment-wholesalers/united-states)
- [Web hosting companies in the United States](https://specstream.ai/data/businesses/web-hosting-companies/united-states)
- [Life insurance agencies in the United States](https://specstream.ai/data/businesses/life-insurance-agencies/united-states)
- [Brewing supply stores in the United States](https://specstream.ai/data/businesses/brewing-supply-stores/united-states)
- [Primary care clinics in the United States](https://specstream.ai/data/businesses/primary-care-clinics/united-states)
